SCHEMBL15049094

SCHEMBL15049094

CCOC(=O)c1sc(-c2cccc(F)c2)nc1NCc1ccc2c(c1)OCO2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 3/20 0.56
▸ CDC7 O00311 2/20 0.53
▸ DBF4 Q9UBU7 2/20 0.53
▸ PDE5A O76074 1/20 0.51
▸ MAPT P10636 5/20 0.51
▸ USP2 O75604 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ ALOX15 P16050 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ DHODH Q02127 1/20 0.48
▸ TSHR P16473 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ PPP1CA P62136 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28246576 0.88 MAPT (0.50) PDE5AMAPTALDH1A1LMNAMEN1
SCHEMBL15049531 0.85 CDC7 (0.73) TRPM8CDC7DBF4MAPTMEN1
SCHEMBL15049461 0.81 CDC7 (0.64) TRPM8CDC7DBF4MAPTALDH1A1
SCHEMBL15049121 0.78 TRPM8 (0.67) TRPM8CDC7DBF4MAPTMEN1
SCHEMBL17318028 0.74 CDC7 (0.73) TRPM8CDC7DBF4ALDH1A1MEN1
SCHEMBL15048962 0.73 TRPM8 (1.00) TRPM8CDC7DBF4MAPTMEN1
SCHEMBL27997076 0.71 CDC7 (0.52) TRPM8CDC7DBF4KDM4EBTK
SCHEMBL17374877 0.71 TRPM8 (0.75) TRPM8CDC7DBF4MAPTLMNA
SCHEMBL28245760 0.71 TRPM8 (0.73) TRPM8CDC7DBF4MAPTALDH1A1
SCHEMBL17317889 0.69 CDC7 (0.81) TRPM8CDC7DBF4MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 — — EP claimed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 — — US claimed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 — — US claimed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 — — US claimed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 — — EP claimed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 — — WO claimed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 — — EP claimed
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 — — EP disclosed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 — — US disclosed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 — — US disclosed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 — — US disclosed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 — — US disclosed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 — — EP disclosed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 — — WO disclosed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129881-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 TRPM8 1/4885CDC7 2527/4885DBF4 3635/4885
US-20140371276-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPV1 TRPM8 1/4885CDC7 3237/4885DBF4 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback